169 related articles for article (PubMed ID: 32348994)
1. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia.
Poh C; Arora M; Ghuman S; Tuscano J
Acta Haematol; 2021; 144(1):95-99. PubMed ID: 32348994
[TBL] [Abstract][Full Text] [Related]
2. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Campbell P; Thomas CM
J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
[TBL] [Abstract][Full Text] [Related]
3. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
4. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Rashidi A; Cashen AF
Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
[TBL] [Abstract][Full Text] [Related]
5. Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature.
Liu Y; Fan L; Zhao H; Xu W; Li J
Oncotarget; 2017 May; 8(19):32292-32297. PubMed ID: 28427176
[TBL] [Abstract][Full Text] [Related]
6. Belinostat: first global approval.
Poole RM
Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience.
Zhu Y; Gao Q; Hu J; Liu X; Guan D; Zhang F
Leuk Res; 2020 Mar; 90():106299. PubMed ID: 32035354
[TBL] [Abstract][Full Text] [Related]
8. Choroidal Infiltration as First Clinical Manifestation of T-cell Large Granular Lymphocyte (T-LGL) Leukemia.
Sarny S; Beham-Schmid C; El-Shabrawi Y
Ocul Immunol Inflamm; 2020 Oct; 28(7):1133-1135. PubMed ID: 31577464
[No Abstract] [Full Text] [Related]
9. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO
Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422
[TBL] [Abstract][Full Text] [Related]
11. T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience.
Sretenovic A; Antic D; Jankovic S; Gotic M; Perunicic-Jovanovic M; Jakovic L; Mihaljevic B
Med Oncol; 2010 Jun; 27(2):286-90. PubMed ID: 19306076
[TBL] [Abstract][Full Text] [Related]
12. Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature.
Alekshun TJ; Tao J; Sokol L
Am J Hematol; 2007 Jun; 82(6):481-5. PubMed ID: 17205534
[TBL] [Abstract][Full Text] [Related]
13. Belinostat for the treatment of peripheral T-cell lymphomas.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
[TBL] [Abstract][Full Text] [Related]
14. Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate.
Munir T; Bishton MJ; Carter I; McMillan A; O'Connor S; Sovani V; Haynes AP; Fox CP
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):705-712. PubMed ID: 27640075
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
Kirschbaum MH; Foon KA; Frankel P; Ruel C; Pulone B; Tuscano JM; Newman EM
Leuk Lymphoma; 2014 Oct; 55(10):2301-4. PubMed ID: 24369094
[TBL] [Abstract][Full Text] [Related]
16. How I treat LGL leukemia.
Lamy T; Loughran TP
Blood; 2011 Mar; 117(10):2764-74. PubMed ID: 21190991
[TBL] [Abstract][Full Text] [Related]
17. [Hepatocellular failure revealing T-cell large granular lymphocyte leukemia: Morocco case study and literature review].
Benmoussa A; Oussaih L; Tazi I
Pan Afr Med J; 2019; 34():119. PubMed ID: 31934260
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
Giaccone G; Rajan A; Berman A; Kelly RJ; Szabo E; Lopez-Chavez A; Trepel J; Lee MJ; Cao L; Espinoza-Delgado I; Spittler J; Loehrer PJ
J Clin Oncol; 2011 May; 29(15):2052-9. PubMed ID: 21502553
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282
[TBL] [Abstract][Full Text] [Related]
20. Distinct effect of cyclophosphamide and cyclosporine on pure red cell aplasia associated with T-cell large granular lymphocyte leukemia.
Tabata R; Tabata C
Int Immunopharmacol; 2014 Dec; 23(2):391-4. PubMed ID: 25466263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
